查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1827957

囊腫纖維化市場（按產品類型、給藥途徑、最終用戶和分銷管道）—2025-2032 年全球預測

Cystic Fibrosis Market by Product Type, Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年囊腫纖維化市場將成長至 136.1 億美元，複合年成長率為 9.80%。

主要市場統計數據
基準年2024年 64.4億美元
預計2025年 70.7億美元
預測年份：2032年 136.1億美元
複合年成長率（%） 9.80%

關於囊腫纖維化產業和政策相關人員面臨的治療要求、複雜臨床護理和策略重點的權威框架

囊腫纖維化是一種遺傳驅動的多系統疾病，持續需要臨床、監管和商業等各學科的協調應對。分子診斷和治療創新的進步正在重塑人們對緩解疾病療法的期望，而藥物可及性、依從性和長期管理的持續挑戰，使疾病繼續成為專科實踐的重中之重。產業、臨床服務和政策層面的相關人員必須在轉化治療方法的前景與切實可行的供應持續性、支付方參與和以病人為中心的服務策略之間取得平衡。

針對潛在蛋白質功能障礙的精準干預，輔以控制感染疾病、發炎和營養需求的藥物，如今已​​成為優先事項。同時，給藥生態系統也在不斷發展：專業藥局途徑、家庭管理模式和數位依從性工具對於維持療效至關重要。臨床醫生和專案經理正在調整護理通訊協定，而支付方則在仔細審查長期價值和比較有效性數據。

綜合考慮這些動態，清晰的策略至關重要。投資人需要了解治療層級與實際利用之間的關係。商業團隊必須根據不斷變化的醫療保健格局調整定價、合約和分銷管道。監管和醫療保健政策專家致力於確保技術創新轉化為切實可行的可及性。本介紹將深入探討變革性轉變、關稅影響、細分市場細微差別、區域差異，以及為引領囊腫纖維化治療領域的領導者提供的建議行動。

評估在現實環境中重塑囊腫纖維化治療途徑和相關人員優先事項的重大臨床、技術和商業性變化

囊腫纖維化領域正在經歷一系列變革，這些變革正在重新定義臨床預期和商業性策略。在治療層面，標靶調變器的出現和迭代改進，正在將醫療服務從症狀控制轉向疾病修飾，改變長期臨床路徑，並提升基於基因型的決策的重要性。隨著這些藥物拓寬了患者預後的視野，臨床醫生和醫療保健系統必須重新調整監測通訊協定、合併症管理和護理過渡流程。

同時，技術創新已超越分子療法。吸入技術、居家輸液實踐和患者支援平台的進步正在重塑依從性和現實世界的有效性。數位化健康干預措施透過遠端監控和遠端醫療在肺部照護中發揮越來越顯著的作用，這些方法正在加速人們對便利性和連續性的期望，尤其是對於那些難以獲得醫療服務的人。

從商業性角度來看，付款人和採購團隊正在轉向基於結果的對話，要求提供強力的真實世界證據來支持長期成本和有效性主張。這種對縱向資料的需求正在推動製造商、臨床網路和病患登記處之間更緊密的合作。同時，隨著相關人員尋求減少中斷並確保患者不間斷地獲得治療，供應鏈的彈性已成為核心考量。治療方法創新必須透過複雜的獲取規劃、證據產生和以病人為中心的交付模式來滿足。

評估 2025 年關稅調整如何改變整個囊腫纖維化治療生態系統的供應鏈策略、採購慣例和營運回應

2025年實施的貿易政策調整和關稅措施對囊腫纖維化治療相關的供應鏈經濟和籌資策略產生了顯著影響。某些藥品投入品和成品關稅的提高改變了製造商和經銷商的到岸成本，促使企業採取直接的營運應對措施，例如與供應商重新協商條款、重新評估採購區域，以及在可行的情況下加快關鍵部件的本地化舉措。這些務實的應對措施旨在控制成本上漲，同時確保需要持續治療的患者獲得所需藥物。

同時，經銷商和專業藥房調整了庫存管理政策，以降低運費波動和關稅不確定性帶來的風險。為了防止治療中斷，延長前置作業時間並在某些供應節點主動儲備物資已成為各機構的常見做法。醫療系統和醫院藥局也重新評估了其採購框架，強調合約彈性和緊急條款，以應對關稅造成的成本波動。

相關人員和產業組織加強了合作，以明確某些治療類別的分類和關稅待遇，特別是複雜生物製藥、組合藥物和給藥裝置。此次對話強調了製定清晰裁決的必要性，以最大限度地減少行政摩擦並支持穩定的供應鏈。最終，2025年關稅變化的累積效應更加重視供應鏈的敏捷性，鼓勵了籌資策略的多樣化，並促使製造商、經銷商和衛生系統之間加強合作，以在不影響臨床護理的情況下保障患者的用藥。

更深入的細分洞察，將治療層級、給藥途徑、護理環境和分銷管道與患者結果和商業策略聯繫起來

細分市場動態揭示了不同治療層級、給藥途徑、最終用戶環境和分銷管道的差異化機會和營運重點。依產品類型分析治療藥物，抗發炎藥物和抗生素仍是症狀治療的關鍵，可應對與潛在遺傳疾病相關的急性和慢性感染及發炎併發症。黏液溶解劑和胰臟酵素在日常症狀管理和營養支持中繼續發揮重要作用，每種藥物都需要穩定的供應和患者的依從性才能維持臨床療效。 CFTR調變器療法帶來了治療模式最顯著的轉變。在這一類別中，Elexacaftor-Tezacaftor-Ivacaftor、Ivacaftor 單藥治療以及 Lumacaftor-Ivacaftor 和 Tezacaftor-Ivacaftor 等組合療法已顯示出在不同基因型之間療效差異，從而推動了影響處方行為、伴隨診斷使用和長期護理計劃的基因型特異性治療途徑。

從給藥途徑來看，吸入療法（可標靶輸送至肺部）仍然是呼吸道症狀管理的主要方法。口服療法（包括多種小分子調節劑和輔助藥物）有利於門診治療，並可在居家醫療中廣泛應用。這些給藥方式的差異會影響依從性模式、監測要求和報銷模式。

終端使用者細分顯示，居家醫療模式擴大透過居家輸液服務和遠端醫療輔助監測來處理複雜的治療方案，從而降低了住院資源利用率。醫院在急性照護事件、複雜診斷和特定輸液方案的啟動方面仍然發揮著重要作用，而專科診所則專注於跨學科協作管理和長期追蹤。分銷通路分析強調了線下藥局網路（包括醫院和零售藥局）對於即時配藥和臨床整合的重要性，以及線上藥局通路的雙重重要性，線上藥局通路可以擴大覆蓋範圍、實現訂閱式交付模式並提供輔助數位支援服務。這些細分揭示了治療方法選擇、交付模式、護理環境和通路如何共同塑造患者體驗、臨床結果和商業策略。

區域比較觀點，重點關注美洲、中東和非洲以及亞太地區的獲取促進因素、監管異質性和證據優先事項

美洲、歐洲、中東和非洲以及亞太地區的區域動態正在對臨床實踐模式、監管方法和可近性框架產生重大影響。在美洲，高度整合的專科護理網路和成熟的支付方途徑促進了基因型定向療法的早期應用，並得到了成熟的註冊和患者權益倡導結構的支持，這些結構有助於促進核准後證據的收集。此類系統通常強調價值的展示和結果的追蹤，強調了支付方協作參與對於確保持續可及性的重要性。

歐洲、中東和非洲 (EMEA) 地區法律規範多樣，報銷環境參差不齊，導致技術採用的時間表和准入門檻各不相同。一些歐洲市場設有集中核准途徑，並配備國家衛生技術評估流程，以審查長期有效性和預算影響。在中東和非洲，基礎設施限制和供應鏈約束可能會減緩技術採用速度，因此需要製定量身定做的打入市場策略和夥伴關係關係，以提升能力和認知度。在全部區域，相關人員優先考慮真實世界證據的產生和當地衛生經濟分析，以支持報銷決策。

在亞太地區，一些市場正在快速採用創新技術，而另一些市場則正經歷法規的演變和國內生物技術能力的不斷提升。在亞太地區的主要市場，國家政策日益支持精準醫療，診斷服務的逐步普及也使得基於基因型的處方成為可能。然而，由於報銷機制和自付費用結構的差異，醫療服務的可近性仍然不均衡。在所有地區，監管協調、供應鏈冗餘以及跨境證據產生合作都是各方關注的焦點，因為相關人員正在努力協調新治療方法的臨床前景與交付和資金籌措的現實。

公司層面的策略分析強調了囊腫纖維化治療持續成功所需的科學差異化、夥伴關係模式和營運彈性

產業參與者佔據著各種策略地位，體現了他們在藥物發現、開發、生產和商業化方面的不同能力。成熟的生物製藥創新者繼續利用其深厚的臨床和監管專業知識來推進下一代調變器和組合方案，而規模較小的生物技術公司和學術衍生公司則推進新機制、基因編輯和遞送平台的早期研究。合約開發和受託製造公司在擴大複雜製劑的生產規模方面發揮關鍵作用，而專業經銷商和藥房服務供應商專注於透過綜合物流和患者支援服務來確保護理的連續性。

夥伴關係和策略聯盟仍然是推動治療產品組合和市場進入的核心。結合臨床開發能力和商業化基礎設施的聯合開發模式，能夠使有前景的化合物快速進入臨床，而與診斷公司簽訂的跨行業協議則支持基因型導向的製劑。許可和共同開發契約透過分散風險和集中專業知識來加速進展。

投資者和企業決策者正密切關注持續商業化所需的營運基礎，包括擴大生產規模、與監管策略保持一致以及產生支持長期報銷的證據。那些儘早整合真實世界證據計畫、展示強大的藥物安全檢測框架並建立可擴展供應鏈冗餘的公司，將更有能力滿足付款人的期望和臨床需求。最終，最具韌性的組織將是那些將科學差異化、務實的營運紀律和積極主動的相關人員參與相結合的公司。

為領導者提供實用的策略指導，使創新、證據生成和供應彈性與付款人參與和以患者為中心的交付模式保持一致

產業領導者應採取多維度策略，將治療創新與可及性、供應彈性和證據生成結合。首先，優先考慮基因型驅動的開發並與伴隨診斷合作，將提升新治療方法的臨床相關性，並為臨床醫生和付款人提供更清晰的價值提案。同時，從開發的早期階段就納入真實世界證據項目，可以解決付款人對長期療效的擔憂，並提供可操作的數據，為指南制定和報銷談判提供參考。

從營運角度來看，實現製造和採購多元化，減少對單一地區供應商或關稅敏感型投入鏈的依賴，有助於保障供應的連續性。領導者應評估近岸外包和雙重採購策略，並加強與物流供應商的合約條款，以降低成本和供應波動。同時，投資專業藥房關係、居家照護支援模式和遠端醫療監測，可以提高患者依從性和體驗，並降低急性加重的可能性，從而避免系統成本的上升。

商業團隊應積極與付款方合作，在適當情況下推廣基於結果的合約機制，並合作建立將臨床指標與報銷掛鉤的註冊登記系統。臨床醫生和病患教育計畫應強調與每種治療層級相符的適當基因分型檢測和臨床路徑。最後，領導者應促進跨部門合作，將研發、診斷、付款方和患者組織聯繫起來，以確保技術創新能夠伴隨實用的、以患者為中心的可及性解決方案。這些聯合行動將形成一種戰略態勢，在創新與現實世界的醫療服務交付考量之間取得平衡。

我們強大的調查方法結合了檢驗的臨床資訊來源、監管分析和供應鏈評估，確保提供可靠、可重複的見解和可行的建議

本分析綜合了同行評審文獻、監管出版物、臨床試驗註冊庫以及來自行業和醫療機構的檢驗的公眾意見，旨在提供囊腫纖維化治療前景的全面視角。數據收集優先考慮了主要臨床資訊、監管決策和既定的患者註冊結果，以確保洞察能夠反映有效的臨床和政策發展。在討論營運或商業實踐時，分析參考了貿易和物流報告、監管指導文件以及已記錄的採購框架，並根據可觀察到的行業行為提出建議。

分析方法結合了定性綜合和比較政策分析。臨床有效性和治療範例的描述源自於總結的試驗結果和指南說明，而營運影響評估則應用基於情境的推理來評估供應鍊和採購反應。證據三角檢定用於識別跨獨立資訊來源的趨勢，敏感性檢定確保結論不依賴任何單一資訊來源的假設。自始至終，我們強調資料來源的透明度，並在存在不確定性的情況下採用保守的措詞。

限制在於，治療方法的核准和監管指南會不斷演變，需要持續監測才能及時了解新證據和政策變化。為了緩解這個問題，我們鼓勵讀者將即時監管更新和註冊資訊作為迭代戰略計劃的一部分，補充報告。該方法旨在支援可重複性，並為有特定臨床或商業性問題的組織提供有針對性的後續分析和客製化資料收集。

綜合關鍵主題，強調需要製定整合策略，將科學突破與營運、付款人和以患者為中心的執行聯繫起來

囊腫纖維化治療的現況既是機會的分水嶺，也是真正的挑戰。科學進步催生了許多可能改變眾多患者疾病軌蹟的治療方法，但要充分發揮其潛力，需要在研發、分銷和政策層面採取協調一致的行動。為了實現永續的可及性，供應鏈的韌性、透過支付方參與的證據產生以及以患者為中心的交付模式對於創新同樣重要。

清晰的策略將有利於那些在科學差異化與營運規範之間取得平衡的機構。那些早期投資真實世界證據、制定靈活交付策略並以透明的療效指標吸引付款方的機構，將能夠將臨床前景轉化為廣泛且永續的效益。相反，如果相關人員將創新和可及性視為不同的優先事項，則可能會因為採購、報銷和患者依從性方面可避免的障礙而導致臨床效益無法實現。

總而言之，前進的道路在於合作。將治療方法進展與分銷、資金籌措和患者支持等切實可行的解決方案相結合，將決定新治療方法能否實現其預期的人群層面影響。隨著該領域的不斷發展，持續監測、對政策變化的靈活回應以及對循證決策的承諾至關重要。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 三重 CFTR調變器療法在廣大患者群體中的快速應用已改善了臨床療效
  • 臨床試驗中針對潛在 CF 突變的 CRISPR 和基因編輯方法的出現
  • 整合遠端醫療平台和遠端監控設備，實現持續的患者管理
  • 擴大專科護理中心網路，支持多學科護理和病患教育
  • 透過病患登記收集真實世界證據來告知 CF 治療的有效性和安全性變得越來越重要。
  • 付款人主導的成本效益評估影響孤兒藥的取得和報銷決策
  • 利用 CFTR 基因分型進行突變特異性治療選擇和療效的個人化醫療舉措不斷成長
  • 開發下一代吸入製劑以增強治療藥物的傳遞和依從性

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第 8 章囊腫纖維化市場（依產品類型）

  • 抗發炎藥物
  • 抗生素
  • CFTR調變器療法
    • 埃萊克卡托 特扎卡托 伊瓦卡托
    • 伊伐卡托
    • 盧馬卡托 伊伐卡托
    • 特扎卡夫托 伊伐卡夫托
  • 黏液溶解劑
  • 胰酶

第9章囊腫纖維化市場（依給藥途徑）

  • 吸入
  • 靜脈
  • 口服

第 10 章囊腫纖維化市場：按最終用戶

  • 家庭醫療保健
  • 醫院
  • 專科診所

第 11 章囊腫纖維化市場（依通路）

  • 線下藥局
    • 醫院藥房
    • 零售藥局
  • 網路藥局

第 12 章囊腫纖維化市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 13 章囊腫纖維化市場：按組

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 14 章囊腫纖維化市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Vertex Pharmaceuticals Incorporated
    • F. Hoffmann-La Roche Ltd
    • Novartis AG
    • Gilead Sciences, Inc.
    • Teva Pharmaceutical Industries Ltd
    • Viatris Inc.
    • Sun Pharmaceutical Industries Ltd
    • Cipla Limited
    • Lupin Limited
    • AbbVie
Product Code: MRR-4316E4E89581

The Cystic Fibrosis Market is projected to grow by USD 13.61 billion at a CAGR of 9.80% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 6.44 billion
Estimated Year [2025] USD 7.07 billion
Forecast Year [2032] USD 13.61 billion
CAGR (%) 9.80%

An authoritative framing of cystic fibrosis therapeutic imperatives, clinical care complexities, and the strategic priorities facing industry and policy stakeholders

Cystic fibrosis is a genetically driven, multisystem disease that continues to demand coordinated clinical, regulatory, and commercial attention. Advances in molecular diagnostics and therapeutic innovation have reshaped expectations for disease-modifying care, while persistent challenges in access, adherence, and long-term management keep the condition at the forefront of specialist practice. Stakeholders across industry, clinical services, and policy must balance the promise of transformative therapies with pragmatic strategies for supply continuity, payer engagement, and patient-centered delivery.

The landscape now prioritizes precision interventions that target underlying protein dysfunction, complemented by agents that manage infection, inflammation, and nutritional needs. Simultaneously, the delivery ecosystem evolves: specialty pharmacy pathways, home-based administration models, and digital adherence tools are increasingly integral to maintaining outcomes. Clinicians and program managers are adapting care protocols while payers scrutinize long-term value and comparative effectiveness data.

Taken together, these dynamics make strategic clarity essential. Investors need to understand how therapeutic classes intersect with real-world utilization. Commercial teams must align pricing, contracting, and distribution with evolving care settings. Regulatory and health policy professionals are focused on ensuring that innovation translates into meaningful access. This introduction sets the stage for a deeper examination of transformative shifts, tariff impacts, segmentation nuances, regional variations, and recommended actions for leaders navigating the cystic fibrosis therapeutic environment.

Evaluating the profound clinical, technological, and commercial shifts reshaping cystic fibrosis care pathways and stakeholder priorities in real-world settings

The cystic fibrosis landscape is undergoing several transformative shifts that together are redefining clinical expectations and commercial strategies. At the therapeutic level, the emergence and iterative improvement of targeted modulators has moved care delivery from symptom control toward disease modification, altering long-term clinical pathways and elevating the importance of genotype-driven decision-making. As these agents extend the horizon of patient outcomes, clinicians and health systems must recalibrate monitoring protocols, comorbidity management, and transition-of-care processes.

Concurrently, innovation is not limited to molecular therapies. Advances in inhalation technologies, home infusion practices, and patient support platforms are reshaping adherence and real-world effectiveness. Digital health interventions now play a more visible role in remote monitoring and telemedicine-delivered pulmonary care, and these modalities have accelerated expectations for convenience and continuity, particularly for populations with access challenges.

From a commercial vantage, payers and procurement groups are shifting toward outcomes-based conversations, requesting robust real-world evidence to support long-term cost and effectiveness claims. This demand for longitudinal data is prompting closer collaboration between manufacturers, clinical networks, and patient registries. Meanwhile, supply chain resilience has become a central consideration as stakeholders seek to mitigate disruptions and ensure uninterrupted patient access. Taken together, these shifts underscore a period of strategic recalibration: therapeutic innovation must be matched by sophisticated access planning, evidence generation, and patient-centric delivery models that collectively determine the long-term success of emerging and established therapies.

Assessing how tariff adjustments enacted in 2025 reshaped supply chain strategies, procurement practices, and operational responses across the cystic fibrosis treatment ecosystem

Trade policy adjustments and tariff actions implemented in 2025 have had a noticeable influence on supply chain economics and procurement strategies relevant to cystic fibrosis therapies. Increased duties on certain pharmaceutical inputs and finished goods altered landed costs for manufacturers and distributors, prompting immediate operational responses such as the renegotiation of supplier terms, reevaluation of sourcing geographies, and accelerated initiatives to localize critical components where feasible. These practical steps sought to contain cost pressures while preserving availability for patients who rely on continuous therapy.

In parallel, distributors and specialty pharmacies adjusted inventory management policies to reduce exposure to freight volatility and tariff uncertainty. Longer lead times and precautionary stocking in some supply nodes became more common as organizations aimed to prevent treatment interruptions. Health systems and hospital pharmacies also reassessed their procurement frameworks, emphasizing contractual flexibility and contingency clauses that account for tariff-driven cost variance.

Regulatory stakeholders and industry groups intensified engagement to clarify classification and duty treatment for specific therapeutic categories, particularly for complex biologics, combination products, and delivery devices. This dialogue emphasized the need for clear rulings that minimize administrative friction and support stable supply chains. Ultimately, the cumulative effect of tariff changes in 2025 has been to heighten attention on supply chain agility, encourage diversification of sourcing strategies, and motivate more robust collaboration among manufacturers, distributors, and health systems to protect patient access without compromising clinical care.

Nuanced segmentation-driven insights that connect therapeutic classes, administration pathways, care settings, and distribution channels to patient outcomes and commercial strategy

Segment-specific dynamics reveal differentiated opportunities and operational priorities across therapeutic classes, administration routes, end-user settings, and distribution channels. When therapies are analyzed by product type, anti-inflammatories and antibiotics remain essential for symptomatic control, addressing acute and chronic infectious and inflammatory complications that accompany the underlying genetic disorder. Mucolytics and pancreatic enzymes continue to play a critical role in day-to-day symptom management and nutritional support, each requiring consistent supply and patient adherence to sustain clinical benefit. CFTR modulator therapy has introduced the most notable inflection in treatment paradigms; within that class, combinations such as Elexacaftor Tezacaftor Ivacaftor, Ivacaftor alone, Lumacaftor Ivacaftor, and Tezacaftor Ivacaftor demonstrate varying efficacy across genotypes, and they have driven genotype-specific treatment pathways that influence prescribing behavior, companion diagnostic use, and long-term care planning.

Considering the route of administration, inhalation therapies provide targeted pulmonary delivery and are central to managing respiratory manifestations, while intravenous formulations are often reserved for severe or refractory infections requiring hospital-based care. Oral therapies, including many small-molecule modulators and supportive agents, facilitate outpatient management and enable broader adoption across home-based care settings. These administration distinctions influence adherence patterns, monitoring requirements, and reimbursement models.

End-user segmentation shows that home healthcare models increasingly accommodate complex regimens through home infusion services and telehealth-supported monitoring, thereby reducing inpatient resource use. Hospitals remain critical for acute care episodes, complex diagnostics, and initiation of certain intravenous regimens, while specialty clinics focus on coordinated multidisciplinary management and longitudinal follow-up. Distribution channel analysis underscores the dual importance of offline pharmacy networks-including hospital and retail pharmacy operations-for immediate dispensing and clinical integration, alongside online pharmacy channels that expand reach, enable subscription delivery models, and deliver ancillary digital support services. Together, these segmentation lenses clarify how therapeutic choice, mode of delivery, care setting, and distribution pathway converge to shape patient experience, clinical outcomes, and commercial strategy.

Comparative regional perspectives highlighting access drivers, regulatory heterogeneity, and evidence priorities across Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics exert meaningful influence on clinical practice patterns, regulatory approaches, and access frameworks across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, highly integrated specialty care networks and established payer pathways foster early adoption of genotype-directed therapies, supported by mature registries and patient advocacy structures that facilitate post-approval evidence collection. These systems often emphasize value demonstration and outcomes tracking, and they underscore the importance of coordinated payer engagement to ensure durable access.

In Europe, the Middle East & Africa region, diverse regulatory frameworks and heterogeneous reimbursement environments create varying uptake timelines and access levels. Centralized approval pathways in some European markets coexist with national health technology assessment processes that scrutinize long-term effectiveness and budget impact. In the Middle East & Africa, infrastructure limitations and supply chain constraints can slow adoption, prompting tailored market-entry strategies and partnerships to build capacity and awareness. Across this combined region, stakeholders prioritize real-world evidence generation and local health economic analyses to support reimbursement decisions.

Asia-Pacific presents a mix of rapid innovation adoption in select markets alongside regulatory evolution and growing domestic biotech capability in others. National policies in key Asia-Pacific markets increasingly support precision medicine, and incremental expansions in diagnostic availability are enabling genotype-based prescribing. However, access can be uneven due to differences in reimbursement mechanisms and out-of-pocket cost structures. Across all regions, cross-border collaboration on regulatory harmonization, supply chain redundancy, and evidence generation is an active focus, as stakeholders attempt to reconcile the clinical promise of new therapies with pragmatic delivery and financing realities.

Strategic company-level analysis emphasizing scientific differentiation, partnership models, and operational resilience required for sustained success in cystic fibrosis therapeutics

Industry participants occupy a range of strategic positions that reflect diverse capabilities in discovery, development, manufacturing, and commercialization. Established biopharmaceutical innovators continue to leverage deep clinical and regulatory expertise to advance next-generation modulators and combination regimens, while smaller biotechnology firms and academic spinouts drive early-stage research into novel mechanisms, gene editing, and delivery platforms. Contract development and manufacturing organizations play a pivotal role in scaling production for complex formulations, and specialty distributors and pharmacy service providers focus on ensuring continuity of care through integrated logistics and patient support services.

Partnerships and strategic alliances remain central to advancing therapeutic portfolios and market access. Collaborative models that pair clinical development capabilities with commercialization infrastructure have enabled faster translation of promising compounds into clinical practice, while cross-sector agreements with diagnostics companies support genotype-directed prescribing. Licensing agreements and co-development arrangements help distribute risk and concentrate expertise where it most accelerates progress.

Investors and corporate decision-makers are attentive to the operational backbone required for sustained commercialization, including manufacturing scale-up, regulatory strategy alignment, and evidence generation to support long-term reimbursement. Companies that integrate real-world evidence programs early, demonstrate robust pharmacovigilance frameworks, and build scalable supply chain redundancies are better positioned to meet payer expectations and clinical needs. Ultimately, the most resilient organizations will be those that combine scientific differentiation with pragmatic operational discipline and proactive stakeholder engagement.

Actionable strategic guidance for leaders to align innovation, evidence generation, and supply resilience with payer engagement and patient-centered delivery models

Industry leaders should adopt a multi-dimensional strategy that aligns therapeutic innovation with access, supply resilience, and evidence generation. First, prioritizing genotype-driven development and companion diagnostic partnerships will increase the clinical relevance of new therapies, enabling clearer value propositions for clinicians and payers. Simultaneously, embedding real-world evidence programs from early phases of development will address payer concerns about long-term effectiveness and provide actionable data to inform guideline development and reimbursement negotiations.

Operationally, diversifying manufacturing and sourcing to reduce exposure to single geographic suppliers and tariff-sensitive input chains will protect continuity of supply. Leaders should evaluate nearshoring or dual-sourcing strategies and strengthen contractual terms with logistics providers to mitigate cost and availability volatility. In parallel, investing in specialty pharmacy relationships, home-care support models, and telehealth-enabled monitoring will improve adherence and patient experience, reducing the likelihood of acute exacerbations that drive higher system costs.

Commercial teams must engage payers proactively, advancing outcomes-based contracting mechanisms where appropriate and collaborating on registries that tie clinical metrics to reimbursement. Education initiatives for clinicians and patients should emphasize appropriate genotype testing and the clinical pathways that align with each therapeutic class. Finally, leaders should cultivate cross-sector collaborations-linking development, diagnostics, payers, and patient organizations-to ensure that innovation is accompanied by practical, patient-centered access solutions. Taken together, these actions create a strategic posture that balances innovation with real-world delivery considerations.

Robust methodological approach combining validated clinical sources, regulatory analysis, and supply chain assessment to ensure reliable, reproducible insights and actionable recommendations

This analysis synthesizes peer-reviewed literature, regulatory publications, clinical trial registries, and verified public statements from industry and health authorities to construct a comprehensive view of the cystic fibrosis therapeutic landscape. Data collection prioritized primary clinical sources, regulatory decisions, and established patient registry outputs to ensure that insights reflect validated clinical and policy developments. Where operational or commercial practices are discussed, the analysis references trade and logistics reporting, regulatory guidance documents, and documented procurement frameworks to ground recommendations in observable industry behavior.

Analytical methods combined qualitative synthesis with comparative policy analysis. Clinical efficacy and treatment paradigm descriptions derive from aggregated trial outcomes and guideline statements, while operational impact assessments applied scenario-based reasoning to evaluate supply chain and procurement responses. Evidence triangulation was used to confirm trends across independent sources, and sensitivity checks ensured that conclusions did not rely on single-source assumptions. Throughout, emphasis was placed on transparency of data provenance and the use of conservative language where uncertainty remains.

Limitations include the evolving nature of therapeutic approvals and regulatory guidance, which requires ongoing monitoring to capture new evidence and policy changes. To mitigate this, readers are encouraged to supplement the report with real-time regulatory updates and registries as part of iterative strategic planning. The methodology supports reproducibility and is designed to facilitate targeted follow-up analyses or bespoke data pulls for organizations with specific clinical or commercial questions.

Synthesis of pivotal themes emphasizing the necessity of integrated strategies that connect scientific breakthroughs with operational, payer, and patient-centered execution

The current moment in cystic fibrosis therapeutics presents both a watershed of opportunity and a set of practical challenges. Scientific progress has generated therapies capable of altering disease trajectories for many patients, but realizing their full potential requires coordinated action across development, distribution, and policy domains. Supply chain resilience, payer-engaged evidence generation, and patient-centric delivery models are equally important to innovation if durable access is to be achieved.

Strategic clarity will favor organizations that pair scientific differentiation with operational discipline. Those that invest early in real-world evidence, cultivate flexible supply strategies, and engage payers with transparent outcome measures will be positioned to translate clinical promise into widespread, sustainable benefit. Conversely, stakeholders that treat innovation and access as separate priorities risk leaving clinical gains unrealized due to avoidable barriers in procurement, reimbursement, or patient adherence.

In conclusion, the path forward is collaborative: integrating advances in therapeutics with pragmatic solutions for distribution, financing, and patient support will determine whether new therapies achieve their intended population-level impact. Continued monitoring, agile responses to policy changes, and a commitment to evidence-driven decision-making will be essential as the field continues to evolve.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid adoption of triple combination CFTR modulator therapies in broad patient populations, improving clinical outcomes
  • 5.2. Emergence of CRISPR and gene editing approaches targeting underlying CF mutations in clinical trial pipelines
  • 5.3. Integration of telehealth platforms and remote monitoring devices for continuous cystic fibrosis patient management
  • 5.4. Expansion of specialty care center networks to support multidisciplinary cystic fibrosis treatment and patient education
  • 5.5. Rising emphasis on real-world evidence collection through patient registries to inform CF therapy effectiveness and safety
  • 5.6. Payer-driven cost-effectiveness evaluations influencing access to cystic fibrosis orphan drugs and reimbursement decisions
  • 5.7. Growth of personalized medicine initiatives leveraging CFTR genotyping for mutation-specific treatment selection and outcomes
  • 5.8. Development of next-generation inhaled formulations to enhance drug delivery and adherence in cystic fibrosis therapy

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cystic Fibrosis Market, by Product Type

  • 8.1. Anti Inflammatories
  • 8.2. Antibiotics
  • 8.3. CFTR Modulator Therapy
    • 8.3.1. Elexacaftor Tezacaftor Ivacaftor
    • 8.3.2. Ivacaftor
    • 8.3.3. Lumacaftor Ivacaftor
    • 8.3.4. Tezacaftor Ivacaftor
  • 8.4. Mucolytics
  • 8.5. Pancreatic Enzymes

9. Cystic Fibrosis Market, by Route Of Administration

  • 9.1. Inhalation
  • 9.2. Intravenous
  • 9.3. Oral

10. Cystic Fibrosis Market, by End User

  • 10.1. Home Healthcare
  • 10.2. Hospitals
  • 10.3. Specialty Clinics

11. Cystic Fibrosis Market, by Distribution Channel

  • 11.1. Offline Pharmacy
    • 11.1.1. Hospital Pharmacy
    • 11.1.2. Retail Pharmacy
  • 11.2. Online Pharmacy

12. Cystic Fibrosis Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Cystic Fibrosis Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Cystic Fibrosis Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Vertex Pharmaceuticals Incorporated
    • 15.3.2. F. Hoffmann-La Roche Ltd
    • 15.3.3. Novartis AG
    • 15.3.4. Gilead Sciences, Inc.
    • 15.3.5. Teva Pharmaceutical Industries Ltd
    • 15.3.6. Viatris Inc.
    • 15.3.7. Sun Pharmaceutical Industries Ltd
    • 15.3.8. Cipla Limited
    • 15.3.9. Lupin Limited
    • 15.3.10. AbbVie

LIST OF FIGURES

  • FIGURE 1. GLOBAL CYSTIC FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. CYSTIC FIBROSIS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. CYSTIC FIBROSIS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CYSTIC FIBROSIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CYSTIC FIBROSIS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CYSTIC FIBROSIS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ANTI INFLAMMATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ANTI INFLAMMATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ANTI INFLAMMATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ANTI INFLAMMATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ANTI INFLAMMATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ANTI INFLAMMATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ELEXACAFTOR TEZACAFTOR IVACAFTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ELEXACAFTOR TEZACAFTOR IVACAFTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ELEXACAFTOR TEZACAFTOR IVACAFTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ELEXACAFTOR TEZACAFTOR IVACAFTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ELEXACAFTOR TEZACAFTOR IVACAFTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ELEXACAFTOR TEZACAFTOR IVACAFTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY IVACAFTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY IVACAFTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY IVACAFTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY IVACAFTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY IVACAFTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY IVACAFTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY LUMACAFTOR IVACAFTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY LUMACAFTOR IVACAFTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY LUMACAFTOR IVACAFTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY LUMACAFTOR IVACAFTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY LUMACAFTOR IVACAFTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY LUMACAFTOR IVACAFTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY TEZACAFTOR IVACAFTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY TEZACAFTOR IVACAFTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY TEZACAFTOR IVACAFTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY TEZACAFTOR IVACAFTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY TEZACAFTOR IVACAFTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY TEZACAFTOR IVACAFTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY MUCOLYTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY MUCOLYTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY MUCOLYTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY MUCOLYTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY MUCOLYTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY MUCOLYTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY PANCREATIC ENZYMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY PANCREATIC ENZYMES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY PANCREATIC ENZYMES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY PANCREATIC ENZYMES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY PANCREATIC ENZYMES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY PANCREATIC ENZYMES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 135. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 137. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. NORTH AMERICA CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. NORTH AMERICA CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2018-2024 (USD MILLION)
  • TABLE 152. NORTH AMERICA CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. LATIN AMERICA CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. LATIN AMERICA CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2018-2024 (USD MILLION)
  • TABLE 166. LATIN AMERICA CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 170. LATIN AMERICA CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 172. LATIN AMERICA CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. MIDDLE EAST CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. MIDDLE EAST CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2018-2024 (USD MILLION)
  • TABLE 208. MIDDLE EAST CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2025-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 210. MIDDLE EAST CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. MIDDLE EAST CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 214. MIDDLE EAST CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 216. MIDDLE EAST CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 217. AFRICA CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. AFRICA CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. AFRICA CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. AFRICA CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. AFRICA CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2018-2024 (USD MILLION)
  • TABLE 222. AFRICA CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2025-2032 (USD MILLION)
  • TABLE 223. AFRICA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 224. AFRICA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 225. AFRICA CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. AFRICA CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. AFRICA CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 228. AFRICA CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 229. AFRICA CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 230. AFRICA CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2018-2024 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2025-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. ASEAN CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. ASEAN CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. ASEAN CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. ASEAN CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. ASEAN CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2018-2024 (USD MILLION)
  • TABLE 252. ASEAN CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2025-2032 (USD MILLION)
  • TABLE 253. ASEAN CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 254. ASEAN CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 255. ASEAN CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. ASEAN CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. ASEAN CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 258. ASEAN CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 259. ASEAN CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 260. ASEAN CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 261. GCC CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GCC CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GCC CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. GCC CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. GCC CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2018-2024 (USD MILLION)
  • TABLE 266. GCC CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2025-2032 (USD MILLION)
  • TABLE 267. GCC CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 268. GCC CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 269. GCC CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. GCC CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 271. GCC CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 272. GCC CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 273. GCC CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 274. GCC CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPEAN UNION CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPEAN UNION CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPEAN UNION CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPEAN UNION CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPEAN UNION CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPEAN UNION CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPEAN UNION CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 289. BRICS CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. BRICS CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. BRICS CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. BRICS CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. BRICS CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2018-2024 (USD MILLION)
  • TABLE 294. BRICS CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2025-2032 (USD MILLION)
  • TABLE 295. BRICS CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 296. BRICS CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 297. BRICS CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 298. BRICS CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 299. BRICS CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 300. BRICS CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 301. BRICS CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 302. BRICS CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 303. G7 CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 304. G7 CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 305. G7 CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. G7 CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 307. G7 CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2018-2024 (USD MILLION)
  • TABLE 308. G7 CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2025-2032 (USD MILLION)
  • TABLE 309. G7 CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 310. G7 CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 311. G7 CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 312. G7 CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 313. G7 CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 314. G7 CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 315. G7 CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 316. G7 CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 317. NATO CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 318. NATO CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 319. NATO CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. NATO CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 321. NATO CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2018-2024 (USD MILLION)
  • TABLE 322. NATO CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2025-2032 (USD MILLION)
  • TABLE 323. NATO CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 324. NATO CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 325. NATO CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 326. NATO CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 327. NATO CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 328. NATO CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 329. NATO CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 330. NATO CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 331. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 332. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 333. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 334. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 335. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2018-2024 (USD MILLION)
  • TABLE 336. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2025-2032 (USD MILLION)
  • TABLE 337. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 338. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 339. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 340. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2025-2032